1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Change of Certified Adviser (CA) to Bergs Securities

MARKN.

Chordate Medical hereby announces that the company has entered into an agreement with Bergs Securities AB for the role of Certified Adviser. Bergs Securities will assume the position of Certified Adviser (CA) on May 2, 2025. Until then, Vator Securities AB will continue to serve as the company’s Certified Adviser.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Change of Certified Adviser (CA) to Bergs Securities

Datum 2025-05-01, kl 09:00
Källa MFN
Bifogade filer
Change of Certified Adviser (CA) to Bergs Securities